BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)

Core Insights - BioNxt Solutions Inc. has reported final results from a preclinical pig study indicating that its proprietary needle-free, swallow-free sublingual oral dissolvable film (ODF) formulation of cladribine for Multiple Sclerosis (MS) shows significantly higher systemic drug delivery compared to conventional oral tablet formulations [1] Group 1: Product Development - The study demonstrates that reformulating cladribine as a sublingual oral dissolvable film can materially improve systemic drug delivery compared to conventional oral tablet dosing [1] - The conventional oral tablet formulation of cladribine, such as those used in Mavenclad®, has reported annual global sales exceeding USD 1.2 billion with sustained double-digit growth [1] Group 2: Market Implications - The results represent an important development milestone for BioNxt, highlighting the potential for enhanced therapeutic efficacy in the treatment of Multiple Sclerosis [1]